To determine whether BTLA, HVEM and LIGHT could be used as new clinical markers of RA, we measured the correlation between the percentage of BTLA+, HVEM+ or LIGHT+ T lymphocytes and the clinical characteristics for RA patients (CRP, RF, ESR, swollen joint count and tender joint count). The gene discussed is CRP; the disease is rheumatoid arthritis.